Literature DB >> 29236517

Epidemiology of Hypersensitivity Pneumonitis among an Insured Population in the United States: A Claims-based Cohort Analysis.

Evans R Fernández Pérez1, Amanda M Kong2, Karina Raimundo3, Tilman L Koelsch4, Rucha Kulkarni2, Ashley L Cole2.   

Abstract

RATIONALE: Hypersensitivity pneumonitis is a complex lung disease resulting from repeated inhalation of a variety of antigens. Limited data exist regarding its epidemiology.
OBJECTIVES: To describe the trends in the annual incidence and prevalence of hypersensitivity pneumonitis in the United States.
METHODS: We developed novel claims-based coding algorithms to identify hypersensitivity pneumonitis, chronic hypersensitivity pneumonitis, and fibrotic hypersensitivity pneumonitis cases using the 2004 to 2013 MarketScan Commercial and Medicare Supplemental healthcare claims databases. Algorithm validity and reliability were assessed with clinical data from National Jewish Health. We calculated yearly cumulative incidence and prevalence overall and by age. For the subgroup with vital status, Kaplan-Meier methods were used to analyze survival stratified by evidence of fibrosis.
RESULTS: We identified 7,498 cases that met our hypersensitivity pneumonitis definition over the 10-year study period, including 3,902 with chronic hypersensitivity pneumonitis and 1,852 with fibrotic hypersensitivity pneumonitis. On the basis of the clinical-radiological adjudication of the validation sample, 38 cases (95%) were confirmed as hypersensitivity pneumonitis. The mean age was 52 years, and 58% were women. The 1-year prevalence rates for hypersensitivity pneumonitis ranged from 1.67 to 2.71 per 100,000 persons, and 1-year cumulative incidence rates ranged from 1.28 to 1.94 per 100,000 persons. The prevalence increased with age, ranging from 0.95 per 100,000 among 0- to 9-year-olds to 11.2 per 100,000 among those aged 65 years and older. Between 56 and 68% of hypersensitivity pneumonitis cases in each year were classified as chronic hypersensitivity pneumonitis (prevalence, 0.91-1.70 per 100,000 persons; cumulative incidence, 0.63-1.08 per 100,000 persons). Fewer had fibrotic hypersensitivity pneumonitis (prevalence, 0.41-0.80 per 100,000 persons; cumulative incidence: 0.29-0.43 per 100,000 persons). Most cases (74%) were classified as unspecified hypersensitivity pneumonitis. Older age, male sex, and fibrosis were associated with higher mortality rates in unadjusted analyses.
CONCLUSIONS: Using U.S. administrative claims-based data, we developed an algorithm with a high sensitivity and specificity for hypersensitivity pneumonitis. Between 2004 and 2013, hypersensitivity pneumonitis was more common among women and those older than 65 years. Most cases were classified as chronic hypersensitivity pneumonitis. Approximately one-fourth met our criteria for fibrotic hypersensitivity pneumonitis, which was associated with a higher mortality rate.

Entities:  

Keywords:  epidemiology; extrinsic allergic alveolitis; farmer’s lung; occupational diseases

Mesh:

Year:  2018        PMID: 29236517     DOI: 10.1513/AnnalsATS.201704-288OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  28 in total

Review 1.  Hypersensitivity pneumonitis.

Authors:  Ulrich Costabel; Yasunari Miyazaki; Annie Pardo; Dirk Koschel; Francesco Bonella; Paolo Spagnolo; Josune Guzman; Christopher J Ryerson; Moises Selman
Journal:  Nat Rev Dis Primers       Date:  2020-08-06       Impact factor: 52.329

2.  S1P1 Contributes to Endotoxin-enhanced B-Cell Functions Involved in Hypersensitivity Pneumonitis.

Authors:  Carole-Ann Huppé; Pascale Blais-Lecours; Emilie Bernatchez; Jean-François Lauzon-Joset; Caroline Duchaine; Hugh Rosen; Geneviève Dion; Kelly M McNagny; Marie-Renée Blanchet; Mathieu C Morissette; David Marsolais
Journal:  Am J Respir Cell Mol Biol       Date:  2020-08       Impact factor: 6.914

3.  Genetic variability of T cell responses in hypersensitivity pneumonitis identified using the BXD genetic reference panel.

Authors:  Jin Wang; Tae Won Yoon; Robert Read; Ae-Kyung Yi; Robert W Williams; Elizabeth A Fitzpatrick
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-01-15       Impact factor: 5.464

4.  Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis.

Authors:  Evans R Fernández Pérez; James L Crooks; Jeffrey J Swigris; Joshua J Solomon; Michael P Mohning; Tristan J Huie; Matthew Koslow; David A Lynch; Steve D Groshong; Kaitlin Fier
Journal:  ERJ Open Res       Date:  2021-06-07

5.  Soldiering on the Job When Ill: Productivity Costs in Connective Tissue Disease-associated Interstitial Lung Disease.

Authors:  Evans R Fernández Pérez
Journal:  Ann Am Thorac Soc       Date:  2020-09

Review 6.  The Occupational Burden of Nonmalignant Respiratory Diseases. An Official American Thoracic Society and European Respiratory Society Statement.

Authors:  Paul D Blanc; Isabella Annesi-Maesano; John R Balmes; Kristin J Cummings; David Fishwick; David Miedinger; Nicola Murgia; Rajen N Naidoo; Carl J Reynolds; Torben Sigsgaard; Kjell Torén; Denis Vinnikov; Carrie A Redlich
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

7.  Clinical characteristics and outcomes of hypersensitivity pneumonitis: a population-based study in China.

Authors:  Li-Jing Wang; Hou-Rong Cai; Yong-Long Xiao; Yang Wang; Meng-Shu Cao
Journal:  Chin Med J (Engl)       Date:  2019-06-05       Impact factor: 2.628

8.  Cladosporium herbarum Hot-Tub Lung Hypersensitivity Pneumonitis in a Greenhouse Worker.

Authors:  João Pedro Abreu; Joana Esteves; Maria Teresa Boncoraglio; Francisca M Pereira; Carla Costa; Carlos Oliveira
Journal:  Eur J Case Rep Intern Med       Date:  2020-03-20

9.  Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Christopher J Ryerson; Jeffrey L Myers; Michael Kreuter; Martina Vasakova; Elena Bargagli; Jonathan H Chung; Bridget F Collins; Elisabeth Bendstrup; Hassan A Chami; Abigail T Chua; Tamera J Corte; Jean-Charles Dalphin; Sonye K Danoff; Javier Diaz-Mendoza; Abhijit Duggal; Ryoko Egashira; Thomas Ewing; Mridu Gulati; Yoshikazu Inoue; Alex R Jenkins; Kerri A Johannson; Takeshi Johkoh; Maximiliano Tamae-Kakazu; Masanori Kitaichi; Shandra L Knight; Dirk Koschel; David J Lederer; Yolanda Mageto; Lisa A Maier; Carlos Matiz; Ferran Morell; Andrew G Nicholson; Setu Patolia; Carlos A Pereira; Elisabetta A Renzoni; Margaret L Salisbury; Moises Selman; Simon L F Walsh; Wim A Wuyts; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-01       Impact factor: 30.528

10.  Reply to Hall et al.: Hypersensitivity Pneumonitis Mortality by Industry and Occupation.

Authors:  Evans R Fernández Pérez; David Sprunger; Pailin Ratanawatkul; Lisa A Maier; Tristan J Huie; Jeffrey J Swigris; Joshua J Solomon; Michael Mohning; Rebecca C Keith; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2019-08-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.